World Health Organization Raises Concern Over Critical Scarcity of Obesity Injections
Under one in 10 people who could benefit from obesity jabs including Wegovy can access them, states the WHO as it releases its initial guidance on the medications.
Considering over a billion people worldwide now living with obesity, it is urging more widespread and fairer availability to this class of drugs.
Based on estimates, over two billion could be living with obesity by 2030 without intervention.
"Our latest guidance acknowledges that obesity is a long-term condition that can be addressed with thorough and continuous care," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are major obstacles to widespread availability to the treatments that can aid individuals in losing significant body mass, explains the agency.
GLP-1 Therapy Scarcity
Despite the present best projected case, the supply of such drugs could only cover around 100 million people – under 10% of those who need them, as stated by the health organization.
The recommendation urges nations and manufacturers to expand access, through strategies such as licensing agreements.
The intellectual property rights on a key compound – the main component of the drug Wegovy – is set to lapse in several countries in 2026.
How Weight-Loss Injections Operate
GLP-1 drugs mimick a natural hormone to slow digestion, curb appetite and enhance the sense of being full so people reduce food intake.
Individuals typically see weight reduction after several weeks of beginning the regular doses.
Studies indicates people may put most of the weight back on a year later of discontinuing the treatment, when their normal appetite return.
Being overweight or obese elevates your likelihood for experiencing diseases, like type 2 diabetes, heart disease, stroke, and certain cancers.
Obesity affects individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
